Globally approved EGFR inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism
Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …
decades ago, and activating RET rearrangements and mutations have since been identified …
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver
activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary …
activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary …
Pathogenesis of cancers derived from thyroid follicular cells
The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …
A comprehensive review of protein kinase inhibitors for cancer therapy
R Kannaiyan, D Mahadevan - Expert review of anticancer therapy, 2018 - Taylor & Francis
Introduction: Protein kinases are involved in various cellular functions. About 2% of the
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …
The importance of the RET gene in thyroid cancer and therapeutic implications
D Salvatore, M Santoro, M Schlumberger - Nature Reviews …, 2021 - nature.com
Since the discovery of the RET receptor tyrosine kinase in 1985, alterations of this protein
have been found in diverse thyroid cancer subtypes. RET gene rearrangements are …
have been found in diverse thyroid cancer subtypes. RET gene rearrangements are …
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
SA Wells Jr, BG Robinson, RF Gagel… - Journal of clinical …, 2012 - ascopubs.org
Purpose There is no effective therapy for patients with advanced medullary thyroid
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular …
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular …
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Activating receptor tyrosine kinase RET (rarranged during transfection) gene alterations
have been identified as oncogenic in multiple malignancies. RET gene rearrangements …
have been identified as oncogenic in multiple malignancies. RET gene rearrangements …
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
C Romei, R Ciampi, R Elisei - Nature Reviews Endocrinology, 2016 - nature.com
The rearranged during transfection (RET) proto-oncogene was identified in 1985 and, very
soon thereafter, a rearrangement named RET/PTC was discovered in papillary thyroid …
soon thereafter, a rearrangement named RET/PTC was discovered in papillary thyroid …
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
K Yoh, T Seto, M Satouchi, M Nishio… - The Lancet …, 2017 - thelancet.com
Background RET rearrangements are rare oncogenic alterations in non-small-cell lung
cancer (NSCLC). Vandetanib is a multitargeted tyrosine kinase inhibitor exhibiting RET …
cancer (NSCLC). Vandetanib is a multitargeted tyrosine kinase inhibitor exhibiting RET …